Proteomic enrichment analysis of psychotic and affective disorders reveals common signatures in presynaptic glutamatergic signaling and energy metabolism

International Journal of Neuropsychopharmacology

Volumn 18, Issue 2, 2015, Pages 1-11

  Gottschalk, Michael G ^a   Wesseling, Hendrik ^a   Guest, Paul C ^a   Bahn, Sabine ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Glutamate; Glycolysis; Proteomics; Psychosis; Systems biology

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CYTOCHROME C; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUTAMATE DECARBOXYLASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE KINASE; SYNAPSIN I; SYNAPTOPHYSIN; SYNAPTOTAGMIN; VESICULAR GLUTAMATE TRANSPORTER 1;

AFFECTIVE PSYCHOSIS; ANALYTIC METHOD; ARTICLE; BIPOLAR DISORDER; BRAIN TISSUE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; ENERGY METABOLISM; GLUCONEOGENESIS; GLUTAMATERGIC SYNAPSE; GLYCOLYSIS; GLYCOSYLATION; HUMAN; HUMAN TISSUE; LIPOLYSIS; MAJOR DEPRESSION; MOOD DISORDER; NEUROTRANSMISSION; OXIDATIVE PHOSPHORYLATION; PREFRONTAL CORTEX; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; PSYCHOSIS; RESPIRATORY CHAIN; SCHIZOPHRENIA; SELECTED REACTION MONITORING; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADULT; BRAIN; COMPARATIVE STUDY; FEMALE; MALE; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; YOUNG ADULT;

ADULT; BIPOLAR DISORDER; BRAIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEOMICS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84931271900     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu019     Document Type: Article

References (88)

1. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psych 156:1646-1649.
2. Alexa A, Rahnenfuhrer J, Lengauer T (2006) Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 22:1600-1607.
3. Altamura CA, Mauri MC, Ferrara A, Moro AR, Dandrea G, Zamberlan F (1993) Plasma and platelet excitatory amino-acids in psychiatric-disorders. Am J Psych 150:1731-1733.
4. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G (2000) Gene ontology: tool for the unification of biology. Nat Genet 25:25-29.
5. Bayes A, Grant SG (2009) Neuroproteomics: understanding the molecular organization and complexity of the brain. Nat Rev Neurosci 10:635-646.
6. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D (2006) Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics 6:3414-3425.
7. Berk M (1999) Lamotrigine and the treatment of mania in bipolar disorder. Eur Neuropsychopharmacol 9(Suppl 4):S119-123.
8. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
9. Blumberg HP, Stern E, Martinez D, Ricketts S, de Asis J, White T, Epstein J, McBride PA, Eidelberg D, Kocsis JH, Silbersweig DA (2000) Increased anterior cingulate and caudate activity in bipolar mania. Biol Psychiatry 48:1045-1052.
10. Boylan LS, Devinsky O, Barry JJ, Ketter TA (2002) Psychiatric uses of antiepileptic treatments. Epilepsy Behav 3:54-59.
11. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR (2001) Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy - Preliminary findings. Arch Gen Psychiatry 58:631-640.
12. Bubber P, Hartounian V, Gibson GE, Blass JP (2011) Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients. Eur Neuropsychopharmacol 21:254-260.
13. Buchsbaum MS, DeLisi LE, Holcomb HH, Cappelletti J, King AC, Johnson J, Hazlett E, Dowling-Zimmerman S, Post RM, Morihisa J, et al. (1984) Anteroposterior gradients in cerebral glucose use in schizophrenia and affective disorders. Arch Gen Psychiatry 41:1159-1166.
14. Cardno AG, Rijsdijk FV, Sham PC, Murray RM, McGuffin P (2002) A twin study of genetic relationships between psychotic symptoms. Am J Psych 159:539-545.
15. Cavelier L, Jazin EE, Eriksson I, Prince J, Bave U, Oreland L, Gyllensten U (1995) Decreased cytochrome-C-oxidase activity and lack of age-related accumulation of mitochondrial- DNA deletions in the brains of schizophrenics. Genomics 29:217-224.
16. Chang CY, Picotti P, Huttenhain R, Heinzelmann-Schwarz V, Jovanovic M, Aebersold R, Vitek O (2012) Protein Significance Analysis in Selected Reaction Monitoring (SRM) Measurements. Mol Cell Proteomics 11:M111.014662.
17. Clark D, Dedova I, Cordwell S, Matsumoto I (2006) A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 11:459-470.
18. Clough T, Thaminy S, Ragg S, Aebersold R, Vitek O (2012) Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs. BMC Bioinformatics 13 Suppl 16:S6.
19. Craddock N, Sklar P (2013) Bipolar disorder 1 genetics of bipolar disorder. Lancet 381:1654-1662.
20. Craddock N, O'Donovan MC, Owen MJ (2009) Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses. Schizophr Bull 35:482-490.
21. Crane GE (1961) The psychotropic effect of cycloserine: a new use of an antibiotic. Compr Psychiatry 2:51-59.
22. Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF (2004) Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 61:450-458.
23. Daniels RW, Collins CA, Chen K, Gelfand MV, Featherstone DE, DiAntonio A (2006) A single vesicular glutamate transporter is sufficient to fill a synaptic vesicle. Neuron 49:11-16.
24. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802.
25. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME (1992) A functional anatomical study of unipolar depression. J Neurosci 12:3628-3641.
26. Eastwood SL, Harrison PJ (2010) Markers of glutamate synaptic transmission and plasticity are increased in the anterior cingulate cortex in bipolar disorder. Biol Psychiatry 67:1010-1016.
27. English JA, Pennington K, Dunn MJ, Cotter DR (2011) The neuroproteomics of schizophrenia. Biol Psychiatry 69:163-172.
28. Erecinska M, Silver IA (1990) Metabolism and role of glutamate in mammalian brain. Prog Neurobiol 35:245-296.
29. Ernst A, Ma D, Garcia-Perez I, Tsang TM, Kluge W, Schwarz E, Guest PC, Holmes E, Sarnyai Z, Bahn S (2012) Molecular validation of the acute phencyclidine rat model for schizophrenia: identification of translational changes in energy metabolism and neurotransmission. J Proteome Res 11:3704-3714.
30. Falcon S, Gentleman R (2007) Using GOstats to test gene lists for GO term association. Bioinformatics 23:257-258.
31. Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, Mallick P, Katz JE, Malmstrom J, Ossola R, Watts JD, Lin BAY, Zhang H, Moritz RL, Aebersold R (2011) A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 10:M110.006353.
32. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatham LN (2012) Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a metaanalysis. Bipolar Disord 14:478-487.
33. Green EK, Grozeva D, Jones I, Jones L, Kirov G, Caesar S, Gordon- Smith K, Fraser C, Forty L, Russell E, Hamshere ML, Moskvina V, Nikolov I, Farmer A, McGuffin P, Holmans PA, Owen MJ, O'Donovan MC, Craddock N (2010) The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 15:1016-1022.
34. Gruber S, Frey R, Mlynarik V, Stadlbauer A, Heiden A, Kasper S, Kemp GJ, Moser E (2003) Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol 38:403-408.
35. Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310-1316.
36. Hoekstra R, Fekkes D, Loonen AJM, Pepplinkhuizen L, Tuinier S, Verhoeven WMA (2006) Bipolar mania and plasma amino acids: Increased levels of glycine. Eur Neuropsychopharmacol 16:71-77.
37. Ingvar DH, Franzen G (1974) Distribution of cerebral activity in chronic schizophrenia. Lancet 2:1484-1486.
38. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984-997, 979.
39. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry 5:142-149.
40. Kato T, Murashita J, Kamiya A, Shioiri T, Kato N, Inubushi T (1998) Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity. Eur Arch Psychiatry Clin Neurosci 248:301-306.
41. Kelley R, Garrett A, Cohen J, Gomez R, Lembke A, Keller J, Reiss AL, Schatzberg A (2013) Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression. Psychiatry Res Neuroimaging 211:119-126.
42. Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS (2007) Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psych 164:778-788.
43. Ketter TA, Kimbrell TA, George MS, Dunn RT, Speer AM, Benson BE, Willis MW, Danielson A, Frye MA, Herscovitch P, Post RM (2001) Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol Psychiatry 49:97-109.
44. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH (1982) Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 232:299-304.
45. Krishnamurthy D, Levin Y, Harris LW, Umrania Y, Bahn S, Guest PC (2011) Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics 11:495-500.
46. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF (2002) Glutamate and GABA systems as targets for novel antidepressant and moodstabilizing treatments. Mol Psychiatry 7:S71-S80.
47. Lamanauskas N, Nistri A (2008) Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci 27:2501-2514.
48. Lange V, Malmstrom JA, Didion J, King NL, Johansson BP, Schafer J, Rameseder J, Wong CH, Deutsch EW, Brusniak MY, Buhlmann P, Bjorck L, Domon B, Aebersold R (2008) Targeted quantitative analysis of Streptococcus pyogenes virulence factors by multiple reaction monitoring. Mol Cell Proteomics 7:1489-1500.
49. Levinson DF (2006) The genetics of depression: a review. Biol Psychiatry 60:84-92.
50. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373:234-239.
51. Lilley KS (2002) Protein profiling using two-dimensional difference gel electrophoresis (2-D DIGE). In: Current Protocols in Protein Science (Coligan JE, Dunn BM, Speicher DW, Wingfield PT, eds), pp. 22.2.1-22.2.14; Hoboken, NJ: John Wiley &Sons.
52. Lu P, Vogel C, Wang R, Yao X, Marcotte EM (2007) Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol 25:117-124.
53. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962) Model psychoses and schizophrenia. Am J Psych 119:61-67.
54. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, Kern R, Tabb DL, Liebler DC, MacCoss MJ (2010) Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26:966-968.
55. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE (2013) Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr Bull 39:120-129.
56. Maurer I, Zierz S, Moller HJ (2001) Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 48:125-136.
57. McCormick LM, Boles Ponto LL, Pierson RK, Johnson HJ, Magnotta V, Brumm MC (2007) Metabolic correlates of antidepressant and antipsychotic response in patients with psychotic depression undergoing electroconvulsive therapy. J ECT 23:265-273.
58. McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, Detera- Wadleigh SD, Steele CJ, Breuer R, Strohmaier J, Wendland JR, Mattheisen M, Muhleisen TW, Maier W, Nothen MM, Cichon S, Farmer A, Vincent JB, Holsboer F, Preisig M, Rietschel M (2010) Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. Nat Genet 42:128-131.
59. Miyatake R, Furukawa A, Suwaki H (2002) Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia. Mol Psychiatry 7:1101-1106.
60. Oberg AL, Vitek O (2009) Statistical design of quantitative mass spectrometry-based proteomic experiments. J Proteome Res 8:2144-2156.
61. Owen MJ, Craddock N, O'Donovan MC (2010) Suggestion of Roles for Both Common and Rare Risk Variants in Genome-wide Studies of Schizophrenia. Arch Gen Psychiatry 67:667-673.
62. Pan C, Kumar C, Bohl S, Klingmueller U, Mann M (2009) Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics 8:443-450.
63. Picotti P, Aebersold R (2012) Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods 9:555-566.
64. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JTJ, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, Webster MJ, Torrey EF, Bahn S (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9:684-697.
65. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-752.
66. Ralhan R, Masui O, Desouza LV, Matta A, Macha M, Siu KW (2011) Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: Strategy for discovery of candidate serological biomarkers. Proteomics 11:2363-2376.
67. Ramnani N, Owen AM (2004) Anterior prefrontal cortex: insights into function from anatomy and neuroimaging. Nat Rev Neurosci 5:184-194.
68. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA, Manji HK (2009) Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine. Biol Psychiatry 65:289-295.
69. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC (2013) Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry, 19:978-985.
70. Shulman RG, Hyder F, Rothman DL (2002) Biophysical basis of brain activity: implications for neuroimaging. Q Rev Biophys 35:287-325.
71. Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurnberger JI, Ripke S, Santangelo S, Sullivan PF (2013) Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381:1371-1379.
72. Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18:207-208.
73. Thompson CM, Davis E, Carrigan CN, Cox HD, Bridges RJ, Gerdes JM (2005) Inhibitor of the glutamate vesicular transporter (VGLUT). Curr Med Chem 12:2041-2056.
74. Timms AE, Dorschner MO, Wechsler J, Choi KY, Kirkwood R, Girirajan S, Baker C, Eichler EE, Korvatska O, Roche KW, Horwitz MS, Tsuang DW (2013) Support for the N-methyl-Daspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 70:582-590.
75. Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S (2007) Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychop 10:557-563.
76. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH (2000) The stanley foundation brain collection and neuropathology consortium. Schizophr Res 44:151-155.
77. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52:829-836.
78. Tsuang MT, Faraone SV (1990) The genetics of mood disorders. Baltimore, MD: The John Hopkins University Press.
79. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000) Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57:1139-1147.
80. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635-645.
81. Volz HR, Riehemann S, Maurer I, Smesny S, Sommer M, Rzanny R, Holstein W, Czekalla J, Sauer H (2000) Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopicimaging study. Biol Psychiatry 47:954-961.
82. Wesseling H, Guest PC, Lago SG, Bahn S (2014) Technological advances for deciphering the complexity of psychiatric disorders: merging proteomics with cell biology. Int J Neuropsychopharmacol. 17:1327-1341.
83. Williams HJ, Craddock N, Russo G, Hamshere ML, Moskvina V, Dwyer S, Smith RL, Green E, Grozeva D, Holmans P, Owen MJ, O'Donovan MC (2011) Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum Mol Gen 20:387-391.
84. Yang X, Levin Y, Rahmoune H, Ma D, Schoffmann S, Umrania Y, Guest PC, Bahn S (2011) Comprehensive two-dimensional liquid chromatography mass spectrometric profiling of the rat hippocampal proteome. Proteomics 11:501-505.
85. Zarate CA, Jr., Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psych 161:171-174.
86. Zarate CA, Jr., Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57:430-432.
87. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
88. Zhang Y, Filiou MD, Reckow S, Gormanns P, Maccarrone G, Kessler MS, Frank E, Hambsch B, Holsboer F, Landgraf R, Turck CW (2011) Proteomic and metabolomic profiling of a trait anxiety mouse model implicate affected pathways. Mol Cell Proteomics 10. doi:10.1074/mcp.M111.008110.